IW Long Reads: How much economic damage can a Covid-19 vaccine repair?

Jab news raises hopes - but cannot fix issues alone

Moderna, Pfizer-BioNTech and now Oxford-AstraZeneca, arriving like buses with not one but three successful early vaccine trials in quick succession, and forecasts of a mass roll out by spring. Miraculous, but it may not be enough to resurrect the sickest parts of the economy. To parrot a now ubiquitous metaphor, vaccine advances have been a shot in the arm for equities. Aviation and hospitality stocks were already buoyed by the Pfizer breakthrough when Moderna revealed its vaccine is 95% effective, sending share prices sharply higher. As Susannah Streeter, senior investment and markets analyst...